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CORRESPONDENCE
Letters to the Editor
Cardioprotection by Volatile
Anesthetics in Noncardiac
Surgery? No, Not Yet At Least
In the recently published article by Fleisher et al. (1), the authors
advise using volatile anesthetics as cardioprotective agents in
patients at risk for myocardial ischemia undergoing noncardiac
surgery. These drugs have indeed shown marked cardioprotective
properties in cardiac surgery, reducing post-operative mortality and
myocardial infarction rate when compared with total intravenous
anesthesia (2).
No study to date has allowed these interesting results to be
translated in noncardiac surgery settings. A recent meta-analysis
including more than 80 randomized controlled studies in which
volatile anesthetics were compared with total intravenous anesthesia
in noncardiac surgery highlighted the complete lack of published
randomized clinical trials reporting data regarding postoperative
mortality or cardiac complications after noncardiac surgery (3),
which indicates that cardioprotection by halogenated anesthetics in
noncardiac surgery is a new and interesting subject that deserves
further study.
Because the authors of the guidelines suggest a class of evidence
IIA, level B (“some conflicting evidence from single randomized
trial or non-randomized studies”), we would appreciate knowing
which article(s) provided the evidence to state that “it can be
beneficial to use volatile anesthetic agents during noncardiac
surgery for the maintenance of general anesthesia in hemodynam-
ically stable patients at risk for myocardial ischemia.”
*Giovanni Landoni, MD
Oliviero Fochi, MD
Alberto Zangrillo, MD
*Department of Cardiothoracic Anesthesia and Intensive Care
Istituto Scientifico San Raffaele, Milano, Italia
Via Olgettina 60
Milan 20132
Italy
E-mail: landoni.giovanni@hsr.it
doi:10.1016/j.jacc.2007.12.020
Please note: Dr. Landoni acknowledges receiving modest support (2,000 €) as a
reimbursement for conferences-symposia.
REFERENCES
1. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007
guidelines on perioperative cardiovascular evaluation and care for
noncardiac surgery: executive summary. A report of the American
College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Writing Committee to Revise the 2002 Guidelines
on Perioperative Cardiovascular Evaluation for Noncardiac Surgery).
J Am Coll Cardiol 2007;50:1707–32.
2. Landoni G, Biondi-Zoccai GG, Zangrillo A, et al. Desflurane and
sevoflurane in cardiac surgery: a meta-analysis of randomized clinical
trials. J Cardiothorac Vasc Anesth 2007;21:502–11.
3. Fochi O, Bignami E, Landoni G, et al. Cardiac protection by volatile
anesthetics in non-cardiac surgery. A meta-analysis (abstr). Minerva
Anestesiol 2007;73 Suppl 2:26.
Reply
There is intense interest in the actions of volatile anesthetics agents
to pre- and post-condition myocardium against injury after myo-
cardial ischemia and reperfusion. Anesthetic pre-conditioning was
first demonstrated in animal models in 1997 (1,2) and in patients
undergoing coronary artery bypass graft surgery in 1999 (3). The
American College of Cardiology/American Heart Association
2007 Guidelines on Perioperative Cardiovascular Evaluation and
Care for Noncardiac Surgery (4) summarize the findings of 15
randomized clinical trials in patients undergoing coronary artery
bypass graft surgery demonstrating that volatile anesthetic agents
decrease troponin release and enhance left ventricular function
compared with several intravenous anesthetics. Studies designed to
evaluate the efficacy of anesthetic pre- or post-conditioning against
myocardial injury have been conducted in patients undergoing
cardiac surgery because the timing and duration of the myocardial
ischemic stimulus is relatively well defined. In addition, the
majority of these investigations controlled for important variables
that could influence anesthetic cardioprotection, such as by dis-
continuing sulfonylurea hypoglycemic agents that block anesthetic
pre- and post-conditioning. The data indicate that volatile
anesthetic agents are protective against myocardial ischemia/
reperfusion injury and can likely be generalized to patients with
coronary artery disease undergoing noncardiac surgery. To date,
there have been no published studies specifically designed to assess
the efficacy of anesthetic pre- or post-conditioning against myo-
cardial injury in patients undergoing noncardiac surgery. Also,
volatile anesthetics produce important negative inotropic effects,
and the risks and benefits of these drugs in hemodynamically
unstable patients are unclear. There is a great need for further
investigation in this area. The conduct of adequately powered and
well-controlled studies of anesthetic cardioprotection in noncar-
diac surgical patients will be challenging. Meta-analyses of heter-
ogeneous clinical trials using volatile or intravenous anesthetics in
patients who are at low or intermediate risk for developing
myocardial ischemia due to the nature of the surgical procedure,
the burden of disease, or both may not be adequate to elucidate the
risks versus benefits of specific anesthetic agents to produce
cardioprotection. Per the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines
Methodology, unpublished data cannot be used to formulate
guideline recommendations. Thus, the weight of the evidence
suggests that volatile anesthetics are protective against myocardial
ischemia/reperfusion injury, and in the absence of data to indicate
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that these commonly used anesthetics increase risk in hemody-
namically stable patients, their use is recommended.
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Biomarker Sensitivity
and Specificity Require
Pre-Test Probability of
Disease Diagnosis to Be Collated
Additional Points on the
Interpretation of Pro–B-Type
Natriuretic Peptide Triage of
Dyspnea in the Copenhagen Heart Study
The Copenhagen City Heart study (1) provides important insight
into community assessment of breathlessness. The report could be
taken to support pro–B-type natriuretic peptide (proBNP) triage
of all breathless patients in this setting. We feel this is a simplistic
analysis of the potential contribution of biomarker technology and
that a number of additional points should be considered.
The relationship of BNP measures to cardiac impairment has
been confirmed, and their utility tested in a variety of settings (1,2).
However, the sampling frame of most surveys (2,3) is of little
relevance to the general practitioner. Importantly in the Copen-
hagen study, 48% of their breathless patients had neither cardiac
nor pulmonary abnormality. In fact, the major causes of dyspnea in
a population-based study were obesity, depression, and older age
(4). Thus, even before addressing the performance of proBNP
analysis, the authors must surely also address the relative diagnostic
void that is presented for almost half of the patients in their study.
Secondly, the incremental value of proBNP testing is not clearly
put in the context of clinical history; physical examination and
simple bedside tests such as a 12-lead electrocardiogram and a
chest roentgenogram. Although these may individually have low
sensitivity and specificity and are operator specific (5,6), they
contribute to pre-test diagnostic probability, which, in turn, affects
the performance of any biomarker and the post-test probability of
the presence of cardiac dysfunction (7). By excluding the contri-
bution of the physician, the ability of the test to function
cost-effectively could alternatively be compromised or enhanced.
Thus, a dyspneic patient with a high proBNP level could undergo
echocardiography, even in the absence of abnormalities on exam-
ination and bedside investigations. Surely in such patients re-
sources would be better employed establishing a noncardiac cause
for dyspnea.
Thirdly, although the authors accounted for age and gender,
they need to interpret point measurement of proBNP levels with
great care due to their large intraindividual and interindividual
variability (33.3% and 36.5%, respectively, in normal individuals
[8]). Both symptomatic and asymptomatic patients with stable
systolic heart failure present with wide ranges of plasma BNP, with
up to 21% of symptomatic patients having BNP levels below what
would be considered “diagnostic”(9).
Finally, the concept that pulmonary disease can be defined by
spirometry alone is not acceptable. This limited technique does not
rule out the presence of significant parenchymal lung disease.
Moreover, proBNP levels can be elevated in lung conditions
resulting in right heart strain and pulmonary hypertension (10,11).
The authors are to be congratulated on their effort in challeng-
ing the use of biomarker technology for the community assessment
of breathlessness. However, its commercial exploitation needs to
be based on its cost-effectiveness and applicability to realistic
clinical practice. It needs to be interpolated in the light of clinical
assessment, particularly given the large percentage of true negative
results for either cardiac or pulmonary abnormalities.
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